Erasca reported updated Phase 1 data for its cancer candidate ERAS-0015 and priced an upsized $550 million public stock offering. Following this, the U.S. FDA granted Fast Track designation to pelareorep for treating advanced anal canal carcinoma. Additionally, Monopar Therapeutics initiated a rolling New Drug Application submission for ALXN1840 to treat Wilson disease.
